Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) is a key target in non-small cell lung cancer (NSCLC) therapy.
• Uncommon EGFR mutations often lead to poor responses to existing EGFR inhibitors.
• Understanding the molecular basis of these diverse responses is crucial for developing effective anti-cancer drugs.

Purpose of the Study:

• To explore the molecular determinants of distinct responses in EGFR mutants (G719S, G719S/L858R, G719S/l861Q) to the EGFR inhibitor Gefitinib (IRE).
• To elucidate how specific mutations affect EGFR stability and inhibitor binding.
• To provide insights for the development of targeted therapies for NSCLC patients with rare EGFR mutations.

Main Methods:

• Computational analysis of molecular interactions within EGFR mutants.
• Assessment of the stability of the αC-helix and K745-E762 salt bridge.
• Evaluation of Gefitinib (IRE) binding affinity and dissociation kinetics for different EGFR mutants.

Main Results:

• Specific residue interactions (S768, D770, Y827, R831) are critical for EGFR stability and salt bridge maintenance.
• The EGFR G719S mutation weakens these interactions, while the G719S/L858R mutation enhances them upon IRE binding.
• Co-occurring mutations can introduce additional hydrogen bonds, further stabilizing the αC-helix.
• Gefitinib (IRE) shows stronger binding affinity to the EGFR G719S/L858R mutant.

Conclusions:

• Rare EGFR mutations significantly impact inhibitor response through altered molecular dynamics.
• The G719S/L858R double mutation enhances Gefitinib binding affinity, suggesting differential therapeutic potential.
• These findings are essential for advancing drug development strategies targeting less common EGFR mutations in NSCLC.